Skip to content

Science Pulse

at Proud ScientistECG · AP · GW

Forum · Medicine · Story discussion

Remibrutinib versus teriflunomide in relapsing multiple sclerosis (REMODEL-1 and REMODEL-2): two randomised, phase 3 trials

Remibrutinib was superior to teriflunomide in patients with relapsing multiple sclerosis, while maintaining a favourable safety profile. These findings support remibrutinib as a potential new oral treatment option for…

28 days ago — The Lancet · Read the original

Peer reviews (0)

Comments (0)

No comments yet. Start the discussion.

Loading sign-in…